The Foundation for AIDS Research (amfAR) released a new issue brief, Expanding Access to Pre-Exposure Prophylaxis (PrEP) for Adolescents and Young Adults: Models for Addressing Consent, Confidentiality, and Payment Barriers. In May 2018, the U.S. Food and Drug Administration approved the once-daily oral medication Truvada as pre-exposure prophylaxis (PrEP) for adolescents to reduce the risk of acquiring HIV. Previously, Truvada was approved as PrEP only for adults aged 18 and older. Ensuring that young people at risk for HIV can access PrEP is a key step toward reducing HIV diagnoses, but will require systematically addressing barriers to access, particularly as it relates to consent, confidentiality. and payment. This brief highlights how three jurisdictions have addressed these barriers through policy change or programs targeting adolescents and young adults.
For more information, view the issue brief.
